

## Procaïnamide (708): sc-66077

### BACKGROUND

Procaïnamide is a class Ia drug used for the clinical treatment of cardiac arrhythmias. It functions by blocking open sodium channels, thereby prolonging the cardiac action potential. This leads to a slowed conduction, and ultimately a decreased rate of rise of the action potential, which may result in widening of QRS on electrocardiogram. The active metabolite in this drug is N-acetyl procaïnamide, which is excreted by the kidneys and the renal system. Procaïnamide may be administered intravenously or orally and can be used for both supraventricular and ventricular arrhythmias. Problematic side effects of Procaïnamide include rash, myalgia, and hypersensitivity reactions. In some cases, Procaïnamide may cause an antibody production against cellular components, which can lead to systemic lupus erythematosus-like reactions.

### REFERENCES

1. Dutcher, J.S., Strong, J.M., Lucas, S.V., Lee, W.K. and Atkinson, A.J. 1977. Procaïnamide and N-acetylprocaïnamide kinetics investigated simultaneously with stable isotope methodology. *Clin. Pharmacol. Ther.* 22: 447-457.
2. Olshansky, B., Martins, J. and Hunt, S. 1982. N-acetylprocaïnamide causing torsades de pointes. *Am. J. Cardiol.* 50: 1439-1441.
3. Giardina, E.G. 1984. Procaïnamide: clinical pharmacology and efficacy against ventricular arrhythmias. *Ann. N.Y. Acad. Sci.* 432: 177-188.
4. Funck-Brentano, C., Light, R.T., Lineberry, M.D., Wright, G.M., Roden, D.M. and Woosley, R.L. 1989. Pharmacokinetic and pharmacodynamic interaction of N-acetylprocaïnamide and Procaïnamide in humans. *J. Cardiovasc. Pharmacol.* 14: 364-373.
5. Marchlinski, F.E., Buxton, A.E., Josephson, M.E. and Schmitt, C. 1989. Predicting ventricular tachycardia cycle length after Procaïnamide by assessing cycle length-dependent changes in paced QRS duration. *Circulation* 79: 39-46.
6. Kim, S.Y. and Benowitz, N.L. 1990. Poisoning due to class IA antiarrhythmic drugs. Quinidine, Procaïnamide and disopyramide. *Drug Saf.* 5: 393-420.
7. Takano, M., Kato, M., Takayama, A., Yasuhara, M., Inui, K. and Hori, R. 1992. Transport of Procaïnamide in a kidney epithelial cell line LLC-PK1. *Biochim. Biophys. Acta* 1108: 133-139.
8. Ellenbogen, K.A., Wood, M.A. and Stamler, B.S. 1993. Procaïnamide: a perspective on its value and danger. *Heart Dis. Stroke* 2: 473-476.
9. Zamponi, G.W., Sui, X., Coddling, P.W. and French, R.J. 1993. Dual actions of Procaïnamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation. *Biophys. J.* 65: 2324-2334.

### SOURCE

Procaïnamide (708) is a mouse monoclonal antibody raised against Procaïnamide.

### PRODUCT

Each vial contains 100 µg IgG<sub>2a</sub> in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

### APPLICATIONS

Procaïnamide (708) is recommended for detection of Procaïnamide by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.